(SMMT) Summit Therapeutics - Ratings and Ratios
Immunotherapy, Antibody, Cancer Treatment, Medicinal Therapies
SMMT EPS (Earnings per Share)
SMMT Revenue
Description: SMMT Summit Therapeutics
Summit Therapeutics PLC (NASDAQ:SMMT) is a biopharmaceutical company focused on developing innovative therapies. Its lead candidate, ivonescimab, is a bispecific antibody in Phase III trials for non-small cell lung cancer treatment, showcasing the companys commitment to immunotherapy and anti-angiogenesis.
Key Performance Indicators (KPIs) to watch include the progress of ivonescimab through clinical trials, as successful trial results could significantly impact the stock price. Additionally, the companys cash burn rate and runway are crucial, given its negative Return on Equity (RoE) of -70.50, indicating substantial investment in research and development. The market capitalization of $20.1B USD suggests a considerable investor base.
From a technical analysis perspective, the stock is currently trading at $26.20, above its 20-day and 50-day Simple Moving Averages (SMA20 and SMA50), indicating a short-term uptrend. The stock has faced resistance at $32.3 and $30.0, with support levels at $26.1, $21.2, and $18.9. The Average True Range (ATR) of 1.57, or 5.98%, suggests moderate volatility.
Given the companys focus on a promising therapeutic candidate and its significant market capitalization, investors should monitor news on ivonescimabs clinical trial progress and the overall biotech sector trends. The absence of a Price-to-Earnings (P/E) ratio is expected for a company with negative earnings, but future profitability will be key to sustained investor interest.
SMMT Stock Overview
| Market Cap in USD | 19,299m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2015-03-05 |
SMMT Stock Ratings
| Growth Rating | 52.2% |
| Fundamental | 33.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -48.2% |
| Analyst Rating | 4.70 of 5 |
SMMT Dividends
Currently no dividends paidSMMT Growth Ratios
| Growth Correlation 3m | 0.5% |
| Growth Correlation 12m | 44.1% |
| Growth Correlation 5y | 39.2% |
| CAGR 5y | 139.58% |
| CAGR/Max DD 3y | 1.85 |
| CAGR/Mean DD 3y | 3.80 |
| Sharpe Ratio 12m | 0.62 |
| Alpha | 0.47 |
| Beta | 0.511 |
| Volatility | 102.56% |
| Current Volume | 6660.4k |
| Average Volume 20d | 3407.5k |
| Stop Loss | 16.8 (-7.3%) |
| Signal | -1.65 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-746.1m TTM) > 0 and > 6% of Revenue (6% = -43.9m TTM) |
| FCFTA -0.44 (>2.0%) and ΔFCFTA -21.41pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -34.05% (prev -80.3k%; Δ 80.2kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.64 (>3.0%) and CFO -207.0m > Net Income -746.1m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 5.13 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (742.6m) change vs 12m ago 4.90% (target <= -2.0% for YES) |
| Gross Margin 102.1% (prev 632.3%; Δ -530.3pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover -219.6% (prev -0.07%; Δ -219.5pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -301.6 (EBITDA TTM -743.2m / Interest Expense TTM 2.46m) >= 6 (WARN >= 3) |
Altman Z'' -58.39
| (A) 0.77 = (Total Current Assets 309.2m - Total Current Liabilities 60.3m) / Total Assets 324.0m |
| (B) -5.69 = Retained Earnings (Balance) -1.84b / Total Assets 324.0m |
| warn (B) unusual magnitude: -5.69 — check mapping/units |
| (C) -2.23 = EBIT TTM -743.2m / Avg Total Assets 332.9m |
| (D) -28.46 = Book Value of Equity -1.84b / Total Liabilities 64.6m |
| Total Rating: -58.39 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 33.61
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -0.75% = -0.37 |
| 3. FCF Margin -19.46% = -7.30 |
| 4. Debt/Equity 0.03 = 2.50 |
| 5. Debt/Ebitda -0.01 = -2.50 |
| 7. RoE -208.6% = -2.50 |
| 8. Rev. Trend -35.79% = -2.68 |
| 9. EPS Trend 29.39% = 1.47 |
What is the price of SMMT shares?
Over the past week, the price has changed by -3.75%, over one month by -31.08%, over three months by -9.17% and over the past year by -38.53%.
Is Summit Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SMMT is around 19.15 USD . This means that SMMT is currently overvalued and has a potential downside of 5.68%.
Is SMMT a buy, sell or hold?
- Strong Buy: 7
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the SMMT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 34.5 | 90.2% |
| Analysts Target Price | 34.5 | 90.2% |
| ValueRay Target Price | 21.2 | 17.2% |
Last update: 2025-09-08 04:50
SMMT Fundamental Data Overview
CCE Cash And Equivalents = 297.9m USD (Cash And Short Term Investments, last quarter)
Revenue TTM is 0, using Net Income TTM -746.1m + Cost of Revenue 15.0m = -731.1m USD
P/S = 753.9008
P/B = 74.388
Beta = -1.027
Revenue TTM = -731.1m USD
EBIT TTM = -743.2m USD
EBITDA TTM = -743.2m USD
Long Term Debt = 4.27m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 3.12m USD (from shortTermDebt, last quarter)
Debt = 7.39m USD (Calculated: Short Term 3.12m + Long Term 4.27m)
Net Debt = -292.3m USD (from netDebt column, last quarter)
Enterprise Value = 19.01b USD (19.30b + Debt 7.39m - CCE 297.9m)
Interest Coverage Ratio = -301.6 (Ebit TTM -743.2m / Interest Expense TTM 2.46m)
FCF Yield = -0.75% (FCF TTM -142.2m / Enterprise Value 19.01b)
FCF Margin = -19.46% (FCF TTM -142.2m / Revenue TTM -731.1m)
Net Margin = -102.1% (Net Income TTM -746.1m / Revenue TTM -731.1m)
Gross Margin = -102.1% ((Revenue TTM -731.1m - Cost of Revenue TTM 15.0m) / Revenue TTM)
Tobins Q-Ratio = -10.34 (set to none) (Enterprise Value 19.01b / Book Value Of Equity -1.84b)
Interest Expense / Debt = 33.34% (Interest Expense 2.46m / Debt 7.39m)
Taxrate = 21.0% (US default)
NOPAT = -743.2m (EBIT -743.2m, no tax applied on loss)
Current Ratio = 5.13 (Total Current Assets 309.2m / Total Current Liabilities 60.3m)
Debt / Equity = 0.03 (Debt 7.39m / last Quarter total Stockholder Equity 259.4m)
Debt / EBITDA = -0.01 (Net Debt -292.3m / EBITDA -743.2m)
Debt / FCF = -0.05 (Debt 7.39m / FCF TTM -142.2m)
Total Stockholder Equity = 357.6m (last 4 quarters mean)
RoA = -230.2% (set to none)
RoE = -208.6% (Net Income TTM -746.1m / Total Stockholder Equity 357.6m)
RoCE = -205.4% (set to none) (Ebit -743.2m / (Equity 357.6m + L.T.Debt 4.27m))
RoIC = -204.3% (set to none) (NOPAT -743.2m / Invested Capital 363.7m)
WACC = 7.91% (E(19.30b)/V(19.31b) * Re(7.90%)) + (D(7.39m)/V(19.31b) * Rd(33.34%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 15.75%
Discount Rate = 7.90% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -142.2m)
EPS Correlation: 29.39 | EPS CAGR: 0.56% | SUE: -2.34 | # QB: False
Revenue Correlation: -35.79 | Revenue CAGR: -21.36%
Additional Sources for SMMT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle